Abstract Library

#4429 Liver transplantation for pancreatic neuroendocrine tumour: A case report

Introduction: The use of liver transplantation for metastatic neuroendocrine tumours is still being explored.

Conference:

Presenting Author: Wang H

Authors: Wang H, Tan H, Zhao H, Chi Y,

Keywords: pancreatic neuroendocrine tumour, liver transplantation, STEM,

#4415 MGMT-activated DUB3 stabilises Nrf2/NCOA4 to modulate apoptosis and ferroptosis, driving temozolomide resistance in pancreatic neuroendocrine tumours

Introduction: O6-methylguanine DNA methyltransferase (MGMT) is a key DNA repair enzyme that removes methyl groups from O(6)-alkylguanine in DNA, introduced by temozolomide (TMZ). Clinical studies in pancreatic neuroendocrine tumours (PanNETs) have confirmed its role in TMZ efficacy.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Chen R, Wang Y, Chen X,

Keywords: pancreatic neuroendocrine tumour, MGMT, temozolomide, ferroptosis,

#4397 DNA repair enzyme regulation strategy for enhanced pancreatic neuroendocrine tumour therapy via targeting siRNA-lipid nanoparticles

Introduction: Pancreatic neuroendocrine tumours (panNETs) originate from neuroendocrine cells with high rates of metastasis, rendering many patients’ ineligible for surgical resection. The first-line chemotherapeutic agent temozolomide (TMZ) for metastatic panNETs faces challenges related to resistance, primarily mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).

Conference:

Presenting Author: Wang F

Authors: Wang F, Xu J, Xu X, Qin Y, Chen J,

Keywords: Lipid nanoparticle, siRNA, DNA repair enzyme, pancreatic neuroendocrine tumour, temozolomide,

#4289 Temozolomide-associated hypermutation and response to immunotherapy in advanced pulmonary neuroendocrine tumours

Introduction: Temozolomide (TMZ) cytotoxicity depends on an intact DNA mismatch repair (MMR) pathway and low levels of O6-methylguanine DNA methyltransferase (MGMT). However, absence of MGMT-mediated repair coupled with defective MMR (dMMR) may lead to enrichment of C:G to A:T transitions throughout the genome, a marked increase in tumour mutational burden (TMB), and loss of TMZ-induced cytotoxicity. This resistance mechanism is called TMZ-associated hypermutation (TAH). Theoretically, this effect could lead to sensitivity to checkpoint inhibitor immunotherapy.

Conference:

Presenting Author: Buikhuisen W

Authors: Buikhuisen W, Badrising S, Moonen L, Derks J, Monkhorst K,

Keywords: Pulmonary NET, whole genome sequencing, temozolomide signature, immunotherapy,

#4029 An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms: MeTe study

Introduction: Metronomic schedule of temozolomide (mTEM) can overcome resistance induced by O6-methylguanine-DNA-methyltransferase (MGMT) and reduce toxicities being particularly suitable for unfit patients (pts). We present the first data from a non-planned interim analysis of this phase II Italian single arm multicenter study.

Conference:

Presenting Author: Spada F

Authors: Spada F, Jemos C, Pisa E, Bagnardi V, Frassoni S,

Keywords: Temozolomide, Metronomic, Chemotherapy, Frailty, MGMT, NEN, NET, QoL,